Stroke - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 563
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6B11FFE7A9EN
Leaflet:

Download PDF Leaflet

Stroke - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Stroke - Pipeline Review, H2 2015’, provides an overview of the Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Stroke Overview
Therapeutics Development
Stroke - Therapeutics under Development by Companies
Stroke - Therapeutics under Investigation by Universities/Institutes
Stroke - Pipeline Products Glance
Stroke - Products under Development by Companies
Stroke - Products under Investigation by Universities/Institutes
Stroke - Companies Involved in Therapeutics Development
Stroke - Therapeutics Assessment
Drug Profiles
Stroke - Recent Pipeline Updates
Stroke - Dormant Projects
Stroke - Discontinued Products
Stroke - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Stroke, H2 2015
Number of Products under Development for Stroke - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Stroke - Pipeline by AB Science SA, H2 2015
Stroke - Pipeline by Acorda Therapeutics, Inc., H2 2015
Stroke - Pipeline by Acticor Biotech, H2 2015
Stroke - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015
Stroke - Pipeline by advanceCor GmbH, H2 2015
Stroke - Pipeline by Affibody AB, H2 2015
Stroke - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Stroke - Pipeline by Anavex Life Sciences Corp., H2 2015
Stroke - Pipeline by Angion Biomedica Corp., H2 2015
Stroke - Pipeline by Antoxis Limited, H2 2015
Stroke - Pipeline by APT Therapeutics, Inc. (Inactive), H2 2015
Stroke - Pipeline by ArmaGen,Inc., H2 2015
Stroke - Pipeline by AstraZeneca Plc, H2 2015
Stroke - Pipeline by Athersys, Inc., H2 2015
Stroke - Pipeline by Bayer AG, H2 2015
Stroke - Pipeline by Bioasis Technologies Inc., H2 2015
Stroke - Pipeline by Biogen, Inc., H2 2015
Stroke - Pipeline by BioTime, Inc., H2 2015
Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
Stroke - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2015
Stroke - Pipeline by CoDa Therapeutics, Inc., H2 2015
Stroke - Pipeline by D-Pharm Ltd., H2 2015
Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Stroke - Pipeline by DiaMedica Inc., H2 2015
Stroke - Pipeline by Digna Biotech, S.L., H2 2015
Stroke - Pipeline by Dong Wha Pharma Co., Ltd., H2 2015
Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Stroke - Pipeline by Fina Biotech, H2 2015
Stroke - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Stroke - Pipeline by Glialogix, Inc., H2 2015
Stroke - Pipeline by Glucox Biotech AB, H2 2015
Stroke - Pipeline by Green Cross Corporation, H2 2015
Stroke - Pipeline by Grifols, S.A., H2 2015
Stroke - Pipeline by Huons Co., Ltd., H2 2015
Stroke - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Stroke - Pipeline by International Stem Cell Corporation, H2 2015
Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Stroke - Pipeline by JN-International Medical Corporation, H2 2015
Stroke - Pipeline by Kolon Life Science, Inc., H2 2015
Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Stroke - Pipeline by Lacer, S.A., H2 2015
Stroke - Pipeline by LegoChem Biosciences, Inc, H2 2015
Stroke - Pipeline by Living Cell Technologies Limited, H2 2015
Stroke - Pipeline by Luc Therapeutics, Inc., H2 2015
Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
Stroke - Pipeline by Mapreg S.A.S., H2 2015
Stroke - Pipeline by Mast Therapeutics, Inc., H2 2015
Stroke - Pipeline by Medestea Research & Production S.p.A., H2 2015
Stroke - Pipeline by MediaPharma s.r.l., H2 2015
Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Stroke - Pipeline by Neuralstem, Inc., H2 2015
Stroke - Pipeline by Neuren Pharmaceuticals Limited, H2 2015
Stroke - Pipeline by Neuronax SAS, H2 2015
Stroke - Pipeline by Neurotec Pharma SL, H2 2015
Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H2 2015
Stroke - Pipeline by New World Laboratories, Inc., H2 2015
Stroke - Pipeline by NoNO, Inc., H2 2015
Stroke - Pipeline by Omeros Corporation, H2 2015
Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Stroke - Pipeline by PharmatrophiX, Inc., H2 2015
Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015
Stroke - Pipeline by Phoenix Biotechnology, Inc., H2 2015
Stroke - Pipeline by Phylogica Limited, H2 2015
Stroke - Pipeline by PhytoHealth Corporation, H2 2015
Stroke - Pipeline by Pozen, Inc., H2 2015
Stroke - Pipeline by Primary Peptides, Inc., H2 2015
Stroke - Pipeline by Q Therapeutics, Inc., H2 2015
Stroke - Pipeline by ReCyte Therapeutics, Inc., H2 2015
Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
Stroke - Pipeline by ReNeuron Group Plc, H2 2015
Stroke - Pipeline by SanBio, Inc., H2 2015
Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015
Stroke - Pipeline by StemCells, Inc., H2 2015
Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Stroke - Pipeline by Sun Pharmaceutical Industries Limited, H2 2015
Stroke - Pipeline by SynZyme Technologies, LLC, H2 2015
Stroke - Pipeline by Targazyme, Inc., H2 2015
Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Stroke - Pipeline by TikoMed AB, H2 2015
Stroke - Pipeline by vasopharm GmbH, H2 2015
Stroke - Pipeline by Vicore Pharma AB, H2 2015
Stroke - Pipeline by Virogenomics, Inc., H2 2015
Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2015
Stroke - Pipeline by Xigen SA, H2 2015
Stroke - Pipeline by Zocere, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Stroke Therapeutics - Recent Pipeline Updates, H2 2015
Stroke - Dormant Projects, H2 2015
Stroke - Dormant Projects (Contd..1), H2 2015
Stroke - Dormant Projects (Contd..2), H2 2015
Stroke - Dormant Projects (Contd..3), H2 2015
Stroke - Dormant Projects (Contd..4), H2 2015
Stroke - Dormant Projects (Contd..5), H2 2015
Stroke - Dormant Projects (Contd..6), H2 2015
Stroke - Dormant Projects (Contd..7), H2 2015
Stroke - Dormant Projects (Contd..8), H2 2015
Stroke - Dormant Projects (Contd..9), H2 2015
Stroke - Dormant Projects (Contd..10), H2 2015
Stroke - Dormant Projects (Contd..11), H2 2015
Stroke - Dormant Projects (Contd..12), H2 2015
Stroke - Discontinued Products, H2 2015
Stroke - Discontinued Products (Contd..1), H2 2015
Stroke - Discontinued Products (Contd..2), H2 2015
Stroke - Discontinued Products (Contd..3), H2 2015
Stroke - Discontinued Products (Contd..4), H2 2015

LIST OF FIGURES

Number of Products under Development for Stroke, H2 2015
Number of Products under Development for Stroke - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AB Science SA
Acorda Therapeutics, Inc.
Acticor Biotech
ActiveSite Pharmaceuticals, Inc.
advanceCor GmbH
Affibody AB
Amarantus Bioscience Holdings, Inc.
Anavex Life Sciences Corp.
Angion Biomedica Corp.
Antoxis Limited
APT Therapeutics, Inc. (Inactive)
ArmaGen,Inc.
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Bioasis Technologies Inc.
Biogen, Inc.
BioTime, Inc.
Cardax Pharmaceuticals, Inc.
Cellular Biomedicine Group, Inc.
CHA Bio & Diostech Co., Ltd.
CoDa Therapeutics, Inc.
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Dong Wha Pharma Co., Ltd.
F. Hoffmann-La Roche Ltd.
Fina Biotech
Generon (Shanghai) Corporation Ltd.
Genervon Biopharmaceuticals, LLC
Glialogix, Inc.
Glucox Biotech AB
Green Cross Corporation
Grifols, S.A.
Huons Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
International Stem Cell Corporation
Jeil Pharmaceutical Co., Ltd.
JN-International Medical Corporation
Kolon Life Science, Inc.
Laboratoires Pierre Fabre SA
Lacer, S.A.
LegoChem Biosciences, Inc
Living Cell Technologies Limited
Luc Therapeutics, Inc.
Lumosa Therapeutics Co., Ltd.
Mapreg S.A.S.
Mast Therapeutics, Inc.
Medestea Research & Production S.p.A.
MediaPharma s.r.l.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
Neuronax SAS
Neurotec Pharma SL
NeuroVive Pharmaceutical AB
New Haven Pharmaceuticals, Inc.
New World Laboratories, Inc.
NoNO, Inc.
Omeros Corporation
Panacea Pharmaceuticals, Inc.
PharmatrophiX, Inc.
Pharmicell Co., Ltd.
Phoenix Biotechnology, Inc.
Phylogica Limited
PhytoHealth Corporation
Pozen, Inc.
Primary Peptides, Inc.
Q Therapeutics, Inc.
ReCyte Therapeutics, Inc.
RegeneRx Biopharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc.
ReNeuron Group Plc
SanBio, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
StemCells, Inc.
Stemedica Cell Technologies, Inc.
Sun Pharmaceutical Industries Limited
SynZyme Technologies, LLC
Targazyme, Inc.
The International Biotechnology Center (IBC) Generium
TikoMed AB
vasopharm GmbH
Vicore Pharma AB
Virogenomics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xigen SA
Zocere, Inc.
Skip to top


Acute Ischemic Stroke - Pipeline Review, H2 2015 US$ 2,000.00 Jul, 2015 · 110 pages
Acute Ischemic Stroke - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 61 pages
Stroke - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 193 pages

Ask Your Question

Stroke - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: